Apellis Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 3/6
Apellis Pharmaceuticals has a total shareholder equity of $266.7M and total debt of $93.1M, which brings its debt-to-equity ratio to 34.9%. Its total assets and total liabilities are $831.9M and $565.3M respectively.
Key information
34.9%
Debt to equity ratio
US$93.11m
Debt
| Interest coverage ratio | n/a |
| Cash | US$333.54m |
| Equity | US$266.68m |
| Total liabilities | US$565.25m |
| Total assets | US$831.93m |
Recent financial health updates
Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way?
Apr 18
Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt Sensibly?
Dec 14Is Apellis Pharmaceuticals (NASDAQ:APLS) A Risky Investment?
Aug 17Recent updates
Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks
May 14Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 09Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain
Feb 16With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For
Jul 19Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week
May 13Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way?
Apr 18Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt Sensibly?
Dec 14Some Analysts Just Cut Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Estimates
Nov 09Apellis Pharmaceuticals: Trying To Develop A Blockbuster Franchise
Sep 28Apellis gains as FDA says AdCom unnecessary for eye disease candidate
Sep 07Is Apellis Pharmaceuticals (NASDAQ:APLS) A Risky Investment?
Aug 17Apellis to exchange $75.6M in convertible senior notes for common stock
Jul 27Apellis stock soars 24% as FDA grants priority review to pegcetacoplan for eye disorder
Jul 19Financial Position Analysis
Short Term Liabilities: APLS's short term assets ($811.4M) exceed its short term liabilities ($215.3M).
Long Term Liabilities: APLS's short term assets ($811.4M) exceed its long term liabilities ($350.0M).
Debt to Equity History and Analysis
Debt Level: APLS has more cash than its total debt.
Reducing Debt: APLS's debt to equity ratio has increased from 3% to 34.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: APLS has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if APLS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.